Table 4.
Univariate analysis of clinical and treatment characteristics and Grade ≥2 pneumonitis by Fisher's exact test or exact Wilcoxon rank-sum test
| Pneumonitis Grade ≥ 2 |
P-value | ||||
|---|---|---|---|---|---|
| No (n = 74) |
Yes (n = 5) |
||||
| n | % | n | % | ||
| Sex | .07 | ||||
| Female | 27 | 36.5 | 4 | 80.0 | |
| Male | 47 | 63.5 | 1 | 20.0 | |
| Median age, years (range) | 60 (21-93) | 69 (47-75) | .28 | ||
| Cancer type | 1.00 | ||||
| Lung | 42 | 56.8 | 3 | 60.0 | |
| Melanoma | 14 | 18.9 | 1 | 20.0 | |
| Other | 18 | 24.3 | 1 | 20.0 | |
| Treatment timing | 1.00 | ||||
| Concurrent | 33 | 44.6 | 2 | 40.0 | |
| Sequential | 41 | 55.4 | 3 | 60.0 | |
| First therapy | .37 | ||||
| Radiation therapy | 35 | 47.3 | 1 | 20.0 | |
| Immunotherapy | 39 | 52.7 | 4 | 80.0 | |
| Immunotherapy category | 1.00 | ||||
| Anti-PD-1 | 45 | 60.8 | 3 | 60.0 | |
| Anti-PD-L1 | 13 | 17.6 | 1 | 20.0 | |
| Anti-CTLA-4 | 11 | 14.9 | 1 | 20.0 | |
| Anti-PD-1/PD-L1+anti-CTLA-4 | 5 | 6.8 | 0 | 0 | |
| Radiation therapy laterality | .45 | ||||
| Right lung | 38 | 51.4 | 2 | 40.0 | |
| Left lung | 24 | 32.4 | 3 | 60.0 | |
| Mediastinum | 12 | 16.2 | 0 | 0 | |
| Radiation therapy technique | .37 | ||||
| Palliative | 44 | 59.5 | 2 | 40.0 | |
| Stereotactic body radiation therapy | 17 | 23.0 | 1 | 20.0 | |
| Other | 13 | 17.6 | 2 | 40.0 | |
| Median radiation therapy dose, cGy (range) | 3000 (1800-7400) | 3000 (2400-6600) | .62 | ||
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.